Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Before that, it dropped the development of another oral GLP-1 called lotiglipron ... Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss ...

Participants who took tirzepatide (Zepbound) dropped an average of 50 pounds over 72 weeks. Those who took semaglutide ...

CVS Health, McKesson’s largest customer ... and lapping the first quarter of 2025 should provide easy comparions. GLP-1 drugs (diabetes and weight-loss) generated about $41 billion in fiscal ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

"In our view, the Novo/CVS deal does not represent the beginning ... company's diabetes drug Mounjaro now make up over half of U.S. GLP-1 prescriptions, outpacing the combined 46% share of Novo ...